Evidence method
Level · gp.fundamentals.debt_to_revenue
1138.92% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
TCRX · Dec 31, 2024
TScan Therapeutics, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0000950170-25-033077General Corporate
Evidence method
Level · gp.fundamentals.capex_revenue_ratio
135.83% · OPTIONAL · VALID
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-3935.44% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
-86.62% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.operating_margin
-4787.68% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
3812.14% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
339.10% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History11 statesHistory building
Dec 31, 20230/7 normalizedLevel 3Mar 31, 20240/7 normalizedLevel 3Jun 30, 20240/7 normalizedLevel 3Sep 30, 20240/7 normalizedLevel 3Dec 31, 20246/7 normalizedLevel 3Mar 31, 20256/7 normalizedLevel 3Jun 30, 20256/7 normalizedLevel 3Sep 30, 20256/7 normalizedLevel 3Dec 31, 20257/7 normalizedLevel 3Mar 31, 20267/7 normalizedLevel 3Jun 30, 20267/7 normalizedLevel 3
Period transition
What moved in the state?
- Previous
- 2921.54%
- Current
- 1138.92%
- Delta
- -1782.62%
- Previous
- 130.60%
- Current
- 135.83%
- Delta
- 5.23%
- Previous
- -2661.39%
- Current
- -3935.44%
- Delta
- -1274.05%
- Previous
- -73.01%
- Current
- -86.62%
- Delta
- -13.61%
- Previous
- -3109.82%
- Current
- -4787.68%
- Delta
- -1677.86%
- Previous
- 2503.53%
- Current
- 3812.14%
- Delta
- 1308.62%
- Previous
- 240.51%
- Current
- 339.10%
- Delta
- 98.58%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · TCRX Fundamental State →Has State · TScan Therapeutics, Inc. →Transitioned To · TCRX Fundamental State →Transitioned To · TCRX BALANCE_SHEET_LEVERAGE_DECREASED →Transitioned To · TCRX CAPEX_INTENSITY_INCREASED →Transitioned To · TCRX CASH_GENERATION_DECREASED →Transitioned To · TCRX GROWTH_DECREASED →Transitioned To · TCRX PROFITABILITY_DECREASED →Transitioned To · TCRX R_AND_D_INTENSITY_INCREASED →Transitioned To · TCRX SBC_INTENSITY_INCREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.